Ads
related to: stelara for crohn's disease- STELARA® Dosing
Dosing & Administration
Important Safety Info
- STELARA® Videos
View Short Educational Videos
to Help Inform Patient Care.
- Patient Resources
Visit HCP Site to
Find Resources for Your Patients.
- STELARA® Clinical Trials
View Clinical Trial Results for
STELARA® Treatment. Learn More.
- Info for Physicians
Physicians - Find Safety, Dosing
& Clinical Data for STELARA®.
- STELARA® Support
Find Cost & Support Resources to
Help Patients With Their Treatment
- STELARA® Dosing
Search results
From Nurse To Patient: My Journey With Crohn’s Disease
Women's Health via Yahoo News· 2 years agoAs a healthcare professional, Alison spent her days doing endoscopies, which are one of the many...
AbbVie's (ABBV) Skyrizi Crohn's Disease Study Meets Goals
Zacks via Yahoo Finance· 8 months agoAbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week...
FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
Benzinga via Yahoo Finance· 11 months agoThe FDA approved AbbVie Inc's (NASDAQ: ABBV) Rinvoq (upadacitinib) for moderately to severely active...
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
Zacks via Yahoo Finance· 1 month agoBristol Myers BMY announced that a late-stage study on orally-administered Zeposia (ozanimod) in...
AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals
Zacks via Yahoo Finance· 2 years agoAbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical...
Analysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast
Reuters via Yahoo Finance· 11 months agoJohnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster...
What Could This Drug News Mean for AbbVie?
Motley Fool· 2 years agoIn late July, AbbVie (NYSE: ABBV) applied for a new indication with the European Medicines Agency (EMA) for Rinvoq to treat adult patients with...
Johnson & Johnson Clocks 12% Q4 Revenue Growth, Led By Cancer and Crohn's Disease Drugs
Benzinga via Yahoo Finance· 3 months agoOn Tuesday, Johnson & Johnson (NYSE:JNJ) reported fourth-quarter 2023 adjusted earnings of $2.29 per...
Lilly's bowel disease drug succeeds in late-stage study
Reuters via Yahoo News· 7 months agoThe drug was also shown not to be inferior to Johnson & Johnson's Stelara in helping symptoms of the...
The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer
Zacks via Yahoo Finance· 5 months agoFor Immediate Release Chicago, IL – November 30, 2023 – Zacks.com announces the list of stocks...
Ads
related to: stelara for crohn's disease